首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1918116

難治性憂鬱症市場－2026-2031年預測

Treatment-Resistant Depression Treatment Market - Forecast from 2026 to 2031

出版日期: 2026年01月14日 | 出版商:

Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2025 年，難治性憂鬱症治療市場規模將達到 37.94 億美元，到 2031 年將達到 53.42 億美元，複合年成長率為 5.87%。

預計在預測期內，難治性憂鬱症（TRD）治療市場將穩定成長，其主要促進因素是相當一部分重度憂鬱症（MDD）患者對第一線和第二線抗憂鬱症治療持續無效。 TRD通常定義為至少兩次足量抗憂鬱症單藥治療無效，影響全球約2.8億憂鬱症成年患者的30%，並與更高的自殺風險、功能障礙和醫療資源利用率相關。

憂鬱症及其難治性形式的全球負擔日益加重，是推動這一成長要素的核心因素，而與憂鬱症直接相關的自殺率上升更是雪上加霜。憂鬱症仍然是導致殘疾的主要原因之一，世界衛生組織的數據顯示，每年約有70萬人死於自殺。未經治療或控制不佳的憂鬱症與自殺之間存在密切關聯，凸顯了有效難治性憂鬱症干預措施的臨床緊迫性。

在持續的國際和國家宣傳活動的支持下，意識提升，正促使人們更積極主動地尋求幫助，並及早識別無反應者。世界衛生組織主導的持續努力、歐洲精神衛生行動計劃的成果、世界精神衛生日宣傳活動以及各國項目，正幫助精神衛生保健正常化，減少歧視，使更多患者能夠進入專科機構接受難治性抑鬱症的診斷和治療。

治療創新主要集中於具有新型作用機制的速效藥物，以克服傳統單胺抗憂鬱症的限制。滴鼻劑esketamine（S-氯胺酮）是目前唯一獲得FDA核准的、專門用於治療難治性抑鬱症（TRD）的治療方法，其真實世界數據表明，該藥物能夠快速且持續地緩解症狀，從而不斷推動治療領域的拓展。在傳統療法中，第二代抗精神病藥物和鋰鹽輔助療法擁有最可靠的實證醫學證據，而具有麩胺酸調節特性的候選藥物也持續推進臨床開發平臺。

北美地區報告的難治性憂鬱症盛行率最高，並憑藉先進的研究基礎設施、快速的法規核准流程以及對藥物和介入療法（例如，經顱磁刺激、電休克療法以及根據風險評估和緩解策略（REMS）使用的艾司esketamine）的有利報銷政策，保持著明顯的市場優勢。該地區受益於大量的製藥投資和成熟的學術性情緒障礙中心網路，這些中心能夠提供複雜的多步驟治療流程。

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 印尼
- 泰國
- 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
企業合併、協議、商業合作
競爭對手儀錶板

第12章：公司簡介

Pfizer Inc
Novartis AG
Johnson & Johnson
AbbVie Inc
Otsuka Pharmaceutical Co., Ltd
Eli Lilly and Company
AstraZeneca Plc
Sage Therapeutics

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
分析方法
簡稱

簡介目錄

Product Code: KSI061615588

The Treatment-Resistant Depression Treatment Market is projected to expand at a 5.87% CAGR, attaining USD 5.342 billion in 2031 from USD 3.794 billion in 2025.

The treatment-resistant depression (TRD) treatment market is projected to expand at a steady pace throughout the forecast period, driven by the persistent failure of first- and second-line antidepressant therapies in a substantial subset of patients with major depressive disorder (MDD). TRD, typically defined as non-response to at least two adequate trials of antidepressant monotherapy, affects approximately 30% of the 280 million adults worldwide with depression and is associated with markedly elevated suicide risk, functional impairment, and healthcare utilization.

Core growth drivers remain the escalating global burden of MDD and its treatment-refractory forms, compounded by heightened suicide rates directly linked to depressive illness. Depression continues to rank among the leading causes of disability, with suicide claiming approximately 700,000 lives annually according to WHO data. The strong correlation between untreated or inadequately managed depression and completed suicide underscores the clinical urgency for effective TRD interventions.

Increased public and professional awareness, supported by sustained international and national campaigns, is translating into higher help-seeking behavior and earlier identification of non-responders. Ongoing WHO-led initiatives, the legacy of the European Mental Health Action Plan, World Mental Health Day mobilization, and national programs continue to normalize mental health care and reduce stigma, funneling greater patient volumes into specialist settings where TRD is diagnosed and managed.

Therapeutic innovation is centered on rapid-acting and mechanistically novel agents that address the limitations of conventional monoaminergic antidepressants. Esketamine (S-ketamine) nasal spray remains the only FDA-approved therapy specifically indicated for TRD and continues to drive category expansion through real-world evidence of rapid and sustained symptom reduction. Augmentation strategies employing second-generation antipsychotics and lithium retain the strongest evidence base among traditional approaches, while glutamate-modulating candidates continue to advance through clinical pipelines.

North America maintains clear market dominance, supported by the highest reported TRD prevalence, advanced research infrastructure, rapid regulatory review pathways, and favorable reimbursement for both pharmacotherapy and interventional modalities (e.g., TMS, ECT, and esketamine administration under REMS). The region benefits from concentrated pharmaceutical investment and a mature network of academic mood-disorder centers capable of delivering complex, multistep treatment algorithms.

Key industry participants are pursuing differentiated mechanisms of action to capture share in this high-unmet-need segment:

Pfizer Inc continues to support PRISTIQ (desvenlafaxine) for MDD while maintaining broader neuroscience capabilities that indirectly bolster TRD management.
Novartis AG is advancing MIJ-821, a direct NMDA receptor antagonist, currently in phase II evaluation for TRD, representing a next-generation effort to replicate and potentially improve upon the esketamine proof-of-concept.
Hikma Pharmaceuticals Plc contributes through its expanding portfolio of generic and specialty injectables that support acute stabilization and augmentation protocols.

The competitive landscape remains dynamic, with established players focusing on life-cycle management of approved assets and emerging biotechnology firms pursuing novel glutamatergic, opioid-modulating, and neuroplasticity-enhancing mechanisms. Increasing venture funding directed toward mental health platforms continues to fuel early-stage research, although post-2023 capital deployment patterns reflect a more selective investment climate.

Overall, the TRD treatment sector is positioned for sustained growth, underpinned by immutable epidemiological trends, progressive destigmatization, and a broadening armamentarium led by esketamine and next-wave NMDA-targeted therapies. North America will continue to lead in market size and innovation velocity, while regulatory approvals and guideline inclusion of rapid-acting agents progressively reshape standard-of-care algorithms for the estimated one-third of MDD patients who fail conventional antidepressant treatment.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Global Treatment-Resistant Depression Treatment Market is analyzed into the following segments:

By Type
Mild
Severe
By Drug Type
NMDA
Antidepressants
Antipsychotics
Others
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Online
Offline
Hospital Pharmacies
Drug Stores
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY TYPE

5.1. Introduction
5.2. Mild
5.3. Severe

6. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DRUG TYPE

6.1. Introduction
6.2. NMDA
6.3. Antidepressants
6.4. Antipsychotics
6.5. Others

7. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY ROUTE OF ADMINISTRATION

7.1. Introduction
7.2. Oral
7.3. Parental
7.4. Others

8. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DISTRIBUTION CHANNEL

8.1. Introduction
8.2. Online
8.3. Offline
- 8.3.1. Hospital Pharmacies
- 8.3.2. Drug Stores

9. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others